Real-World Response Rates across Lines of Therapy Among Patients with Relapsed/Refractory Follicular Lymphoma
Improved lifelines needed for all lines: real-world treatment patterns and attrition rates in US patients with non-driver mutation metastatic non-small cell lung cancer
Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases
XX International workshop on chronic lymphocytic leukemia
TREATMENT PATTERNS AND REAL-WORLD OUTCOMES OF MOLECULAR SUBGROUPS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING FRONTLINE VENETOCLAX-BASED THERAPY
REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT OUTCOMES OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) BY LINE OF THERAPY (LOT)
REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)
